Article

Systemic effects of orally-administered zinc and tin (IV) metalloporphyrins on heme oxygenase expression in mice

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305-5208, USA.
Pediatric Research (Impact Factor: 2.84). 06/2006; 59(5):667-72. DOI: 10.1203/01.pdr.0000215088.71481.a6
Source: PubMed

ABSTRACT Some metalloporphyrins (Mps) inhibit heme oxygenase (HO), the rate-limiting enzyme in the production of bilirubin, and are potential compounds for the treatment of neonatal jaundice. We studied the safety and efficacy of Mps following oral administration. Adult HO-1-luc reporter mice were administered 30 micromol/kg body weight of tin mesoporphyrin (SnMP), zinc bis glycol deuteroporphyrin (ZnBG), or zinc protoporphyrin (ZnPP), or vehicle by oral gavage. Bilirubin production was measured as total body carbon monoxide (CO) excretion (VeCO). HO activity was quantitated via CO measurements by gas chromatography. HO-1 protein was determined by Western blot. HO-1 transcription levels were assessed by in vivo bioluminescence imaging. A significant 28% decrease in bilirubin production occurred within 3 h of SnMP treatment and persisted beyond 48 h. Bilirubin production decreased 15% and 9% by 3 h after administration of ZnBG and ZnPP, respectively, but returned to baseline within 48 h. Maximal inhibition of liver, spleen, and intestine HO activity was seen at 3 h with inhibitory effects decreasing in the order: SnMP > or = ZnBG > or = ZnPP. After SnMP treatment, HO-1 transcription increased 5.7-fold after 24 h. Furthermore, liver and spleen HO-1 protein significantly increased 3.7- and 2.0-fold, respectively, after 24 h. HO-1 transcription and protein were not affected in ZnBG- or ZnPP-treated mice. We conclude that the three Mps are absorbed at different rates in the mouse and affect bilirubin production and HO-1 expression in a tissue- and time-dependent manner.

Download full-text

Full-text

Available from: Christopher H Contag, May 20, 2014
0 Followers
 · 
76 Views
  • Source
    • "One transcriptional consequence of Fh1 deficiency is Hmox1 upregulation. Since Hmox1 is cardioprotective (Melo et al., 2002; Piantadosi et al., 2008; Soares et al., 1998; Yet et al., 2001), we hypothesized that Hmox1 contributed to fumaraterelated cardioprotection and assessed the effect of zinc deuteroporphyrin 2,4-bis glycol (ZnBG), a well-established and relatively specific Hmox1 inhibitor (Vreman et al., 1991; Appleton et al., 1999; Zhang et al., 2002; Morioka et al., 2006; Czibik et al., 2009). Inhibition of Hmox1 by ZnBG abrogated cardioprotection in the Fh1 KO hearts (33.3% ± 2.2% control; 11.4% ± 1.5% Fh1 KO; 30.1% ± 2.7% control + ZnBG; 35.2% ± 4.6% Fh1 KO + ZnBG; Fh1 KO ANOVA p < 0.001 versus all other groups) (Figure 4E). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The citric acid cycle (CAC) metabolite fumarate has been proposed to be cardioprotective; however, its mechanisms of action remain to be determined. To augment cardiac fumarate levels and to assess fumarate's cardioprotective properties, we generated fumarate hydratase (Fh1) cardiac knockout (KO) mice. These fumarate-replete hearts were robustly protected from ischemia-reperfusion injury (I/R). To compensate for the loss of Fh1 activity, KO hearts maintain ATP levels in part by channeling amino acids into the CAC. In addition, by stabilizing the transcriptional regulator Nrf2, Fh1 KO hearts upregulate protective antioxidant response element genes. Supporting the importance of the latter mechanism, clinically relevant doses of dimethylfumarate upregulated Nrf2 and its target genes, hence protecting control hearts, but failed to similarly protect Nrf2-KO hearts in an in vivo model of myocardial infarction. We propose that clinically established fumarate derivatives activate the Nrf2 pathway and are readily testable cytoprotective agents.
    Cell metabolism 03/2012; 15(3):361-71. DOI:10.1016/j.cmet.2012.01.017 · 16.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In dieser Studie wurden die Auswirkungen der pharmakologischen Blockade der Hämoxygenase mittels Sn-mesoporphyrin auf myokardiales Stunning bei wachen, chronisch instrumentierten Hunden untersucht. Es wurden sechs Hunde der Rasse „Foxhound“ in Allgemeinanästhesie instrumentiert. Messsonden wurden eingebracht, mit deren Hilfe Herzfrequenz, arterieller Blutdruck, linksatrialer Druck, links-ventrikulärer Druck, Blutflussgeschwindigkeit im Ramus interventricularis anterior (RIVA) der linken Koronararterie und die myokardiale Wanddickenfraktion (WDF) aufgezeichnet werden konnten. Um den RIVA wurden Ballonokkluder gelegt, um kurzzeitige Ischämien im RIVA-perfundierten Myokardbereich zu induzieren. Die regionale myokardiale Perfusion konnte mit Hilfe gefärbter Mikrosphären postmortal bestimmt werden.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: De ziekte van Crigler-Najjar is een ernstige, weinig voorkomende vorm van geelzucht. Kenmerk van de ziekte is ophoping in het lichaam van ongeconjugeerd bilirubine (UCB), een afbraakproduct van rode bloedcellen. Ophoping van UCB kan leiden tot neurologische schade. De gebruikelijke behandeling van de ziekte is fototherapie, waarbij de patiënt dagelijks vele uren onder een soort zonnebank moet doorbrengen. Dit tast het sociale leven van de patiënt erg aan. Bovendien wordt de behandeling met het stijgen van de leeftijd minder effectief. Promovendus Anja Hafkamp deed onderzoek naar een nieuwe behande­ling van deze ziekte. Doel was UCB in de darmen te “vangen” door middel van vet. Dit voorkomt heropname van UCB vanuit de darm in het lichaam. Door oraal toe te dienen medicatie werd de vetuitscheiding en daarmee de UCB uitscheiding via de ontlasting bevorderd. Bij patiënten met de ziekte van Crigler-Najjar waren de effecten relatief beperkt. Echter, een subgroep van de patiënten reageerde wél op de behandeling. Nader onderzoek moet duidelijk maken wat de verschillen veroorzaakt. Hafkamp verwacht dat deze nieuwe behandelmethode in de toekomst toegepast kan worden.
Show more